Evidence map›Paper›PMID 36634295›Full record

ArticleJCO precision oncology2023

Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Mir Lim, Patrick T Lynch, Xiaochen Bai, David Hsiehchen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Case Report: FGFR2 inhibitor resistance viaFrontiers in oncology · 2025
    Article
  5. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mir LimDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-6102-0887
Patrick T LynchDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0001-8127-5812
Xiaochen BaiDepartment of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX.
David HsiehchenDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-0602-7445
The University of Texas Southwestern Medical Center · US

Funding

Structural insights into the unique activation mechanisms of receptor tyrosine kinasesR01GM143158 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI BAI, XIAOCHEN · 2021 to 2024
$1.6M
NIGMS NIH HHS R01 GM143158
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaBile Ducts, IntrahepaticHumansLigandsMorpholinesPyrimidinesPyrrolesReceptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanLigandsMorpholinespemigatinibPyrimidinesPyrrolesReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID36634295
PMCPMC11852385
OpenAlexW4315750050

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.